Immunome
IMNM
142 hedge funds and large institutions have $739M invested in Immunome in 2025 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 55 increasing their positions, 38 reducing their positions, and 26 closing their positions.
45% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 38
42% more capital invested
Capital invested by funds: $518M → $739M (+$220M)
2.8% more ownership
Funds ownership: 88.49% → 91.29% (+2.8%)
4% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 26
0% more funds holding
Funds holding: 142 → 142 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
97% less call options, than puts
Call options by funds: $1.07M | Put options by funds: $39.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.7M |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$17.1M |
| 3 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
+$9.26M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$8.2M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$5.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$10.2M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$8.59M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.22M |
| 4 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$5.05M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$4.01M |
IMNM Hedge Fund Activity: Q2 2025 in Review
142 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q2 2025, worth a combined $739M — up 42% from $518M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new IMNM positions and 26 closed out — a net gain of 1 holder — while 55 added to existing stakes and 38 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $18.7M. The largest seller was Susquehanna International Group, cutting an estimated $10.2M.
- 142 institutional investors held Immunome (IMNM) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $739M of Immunome stock for Q2 2025, up 42% quarter-over-quarter.
- 27 funds opened new Immunome positions in Q2 2025 and 26 closed out, a net change of +1 holder.
- The largest Immunome buyer in Q2 2025 was Fidelity Investments, an estimated $18.7M added.
- The largest Immunome seller in Q2 2025 was Susquehanna International Group, an estimated $10.2M sold.
Based on aggregated 13F filings for Q2 2025.